Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma | NEJM
Patients with renal-cell carcinoma who undergo nephrectomy have no options for adjuvant therapy to reduce the risk of recurrence that have high levels of supporting evidence. In a double-blind, pha…